Sayed Ali, MD
Nephrology · Manhasset, NYNPI 1194721191
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,578 of the $41,453 with a category attached, or 66.5%. AstraZeneca accounts for 78.2% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $12,145 and has fallen 83.0% since, to $2,066 in 2025. Among nephrology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 500 payments — averaging $82.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$32K
- Amgen$2K
- Mallinckrodt Hospital Products Inc.$882
- Otsuka America Pharmaceutical, Inc.$787
- Vifor Pharma, Inc.$694
- OPKO Pharmaceuticals, LLC$588
- plus $4K from 31 others
Across 3 payments — averaging $25,958 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$78K
What the payments were for
- Consulting fees$1,2243%
- Speaking & faculty fees$27,57867%
- Travel & lodging$1,2703%
- Food & beverage$10,94926%
- Education$4321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 132 | $32,408 |
| Amgen(2 entities) | 46 | $2,360 |
| Mallinckrodt Hospital Products Inc. | 35 | $882 |
| Otsuka America Pharmaceutical, Inc. | 35 | $787 |
| Vifor Pharma, Inc. | 31 | $694 |
| OPKO Pharmaceuticals, LLC | 48 | $588 |
| Bayer | 13 | $328 |
| Novo Nordisk | 20 | $324 |
| ANI Pharmaceuticals, Inc. | 13 | $323 |
| Novartis | 13 | $276 |
| Lilly USA, LLC | 17 | $224 |
| Johnson & Johnson | 5 | $219 |
| Akebia Therapeutics Inc | 11 | $216 |
| Fresenius USA Marketing, Inc. | 10 | $203 |
| Boston Scientific | 2 | $181 |
| Daiichi Sankyo Inc. | 8 | $172 |
| Travere Therapeutics, Inc. | 9 | $156 |
| Aurinia Pharma U.S., Inc. | 6 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $122 |
| Mallinckrodt Enterprises LLC | 6 | $117 |
| Boehringer Ingelheim | 4 | $108 |
| Scpharmaceuticals Inc. | 5 | $106 |
| Renalytix AI, Inc. | 5 | $102 |
| Ardelyx, Inc. | 4 | $91 |
| Fresenius USA Manufacturing, Inc. | 2 | $44 |
| Shire North American Group Inc | 2 | $41 |
| AbbVie | 1 | $35 |
| Pfizer | 1 | $32 |
| Ascendis Pharma Endocrinology Inc | 1 | $30 |
| Calliditas Therapeutics US Inc. | 2 | $27 |
| GSK | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Abiomed | 1 | $18 |
| Medtronic | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Seqirus USA Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$28,220
- FARXIGA$2,175
- KRYSTEXXA$1,328
- Varithena Administration Pack$164
- XARELTO$125
How this compares
$41,453 in reported general payments places this provider in the 90th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 80 | $111,473 |
| LokelmaSodium Zirconium Cyclosilicate | 70 | $95,125 |
| OzempicSemaglutide | 35 | $50,769 |
| Cinacalcet Hcl | 35 | $47,191 |
| JardianceEmpagliflozin | 23 | $35,891 |
| EliquisApixaban | 26 | $35,664 |
| TrulicityDulaglutide | 11 | $11,059 |
| JanuviaSitagliptin Phosphate | 14 | $11,047 |
| Lanthanum Carbonate | 11 | $11,040 |
| Sevelamer Carbonate | 28 | $4,382 |
| Tacrolimus | 14 | $3,312 |
| Olmesartan Medoxomil | 65 | $1,607 |
| Nifedipine ErNifedipine | 28 | $1,198 |
| Midodrine Hcl | 14 | $1,170 |
| Metolazone | 39 | $1,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $32,408 | $206,599150 claims |
| Novo NordiskOzempic | $324 | $50,76935 claims |
| Boehringer IngelheimJardiance | $108 | $35,89123 claims |
| PfizerEliquis | $32 | $35,66426 claims |
| Lilly USA, LLCTrulicity | $224 | $11,05911 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $323 | $80229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 nephrology providers in New York.
Other nephrology in Manhasset
- Gerard TepedinoManhasset$308K
- Jeffrey CohenManhasset$69K
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Bruce SpinowitzBronx$465K
- Steven CocaNew York$445K
- Joseph RoglieriTroy$425K
- Jai RadhakrishnanNew York$369K
- Savneek ChughHawthorne$325K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.